Why The Narrative Around United Therapeutics Is Shifting After Major Clinical and Pipeline Updates [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
from $484.77 to $492.85, reflecting a modest increase in expected intrinsic value. This adjustment comes alongside a marginal uptick in the discount rate from 6.78% to 6.81%, signaling a small change in the risk outlook for future cash flows. Revenue growth estimates dipped only minimally. Stay tuned to discover how you can keep a pulse on these evolving market expectations as the narrative around the stock continues to unfold. What Wall Street Has Been Saying ?? Bullish Takeaways Several firms have raised their price targets in response to strong clinical trial data and growth prospects for United Therapeutics, particularly around TYVASO in idiopathic pulmonary fibrosis (IPF). Jefferies raised its price target to $564 from $432 and maintains a Buy rating, calling the recent Phase 3 IPF study for Tyvaso a “significant upside surprise” and emphasizing the competitive and clinically meaningful results. The firm also notes the possibility for expedited regulatory review based on
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base [Yahoo! Finance]Yahoo! Finance
- United Therapeutics: Growing Company With Great Franchise In Pulmonary Diseases [Seeking Alpha]Seeking Alpha
- United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 12/4/25 - Form 144
- 12/3/25 - Form 144
- 12/2/25 - Form 4
- UTHR's page on the SEC website